TxCell cooperates with Lonza for making CAR-Tregs

16/08/2018
13.jpg
        

          TxCell is a pharmaceutical manufacturer, who uses patients’ immunosuppression (regulatory T-cell : Tregs), has collaborated with Lonza to produce pharmaceutical products by using HLA-A2 CAR-Treg.

          HLA-A2 CAR-Tregs is one of the most advanced treatment by using immunosuppression. It demonstrates the prevention of organ rejection after organ transplant process. This technology is based on the work of Prof. Megan Lewings and his colleagues from the University of British Columbia (UBC) in Canada. TxCell has collaborated in this research and development since 2016.
 
Page view : 44